Roche (RHHBY.PK) announced that it has received clearance from the U.S. Food and Drug Administration or FDA for the Accu-Chek Combo system for insulin pump therapy. The company said that the system will be available in the United States in the second half of 2012.
The company said that the Accu-Chek Combo system seamlessly combines a blood glucose meter with an insulin pump, which are able to exchange data in both directions via Bluetooth wireless technology.
According to the company, the meter not only enables the user to quickly test blood glucose levels: It allows for operating the insulin pump remotely and by means of an easy-to-handle bolus advisor it provides support in defining the right amount of insulin. With this the Accu-Chek Combo system not only supports a more targeted therapy management, but it also allows for a discreet insulin administration without the need to touch the pump.
The company noted that the Accu-Chek Combo system has been launched successfully in several European and Asia-Pacific countries already - including France, Germany, UK, and Australia.
Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com